Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (1744)	4/29/2015 11:29:36 AM
From: Biotech Jim	Read Replies (1) \| Respond to of 3559

I do know that George Y is bullish on this target and Ab. His early work was in muscle biology. The path for sarcopenia approval needs to be paved with the FDA. One advantage of a mAb for sarcopenia is that it is hard to imitate the drug and put it on the black market. Doping of small molecule drugs for enhanced muscle performance is HUGE. There is a USA anti-doping agency. usada.org "Overview: The U.S. Anti-Doping Agency (USADA), runs the anti-doping program including education, sample collection, results management, and drug reference resources for athletes in U.S. Olympic, Paralympic, Pan American, and Parapan American Sport, including all Olympic sport national governing bodies, their athletes, and events throughout the year. Additionally, USADA’s commitment to clean competition and the integrity of competition also includes programs aimed at scientific research and education & outreach initiatives focused on awareness and prevention. USADA is a signatory to the World Anti-Doping Code and fully complies with the World Anti-Doping Code’s International Standards. Our anti-doping program, which includes policies & procedures, highly trained office staff, and doping control is often referred to as the gold standard in anti-doping globally and is at the forefront of the fight for clean competition."